Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC

Carmine Pinto, Nicola Normanno, Armando Orlandi, Francesca Fenizia, Angela Damato, Evaristo Maiello, Emiliano Tamburini, Francesco Di Costanzo, Giuseppe Tonini, Domenico Bilancia, Domenico Corsi, Salvatore Pisconti, Francesco Ferrau, Stefania Gori, Bruno Daniele, Alberto Zaniboni, Hector Soto Parra, Giovanni Luca Frassinetti, Rosario Vincenzo Iaffaioli, Antonio CassataMaria Giulia Zampino, Lazzaro Repetto, Maria Alessandra Calegari, Carlo Barone

Research output: Contribution to journalArticlepeer-review

Abstract

The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients.
Original languageEnglish
Pages (from-to)1339-1346
Number of pages8
JournalFuture Oncology
Volume14
Issue number14
DOIs
Publication statusPublished - Jun 1 2018

Keywords

  • cetuximab
  • colorectal cancer
  • de-escalation therapy
  • RAS and BRAF wild-type

Fingerprint Dive into the research topics of 'Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC'. Together they form a unique fingerprint.

Cite this